Image (07df0165 3f2e 4f1c 91cc F81c3f7173d7 151 1)
Pregabalin Capsule
Product Images NDC 29300-444
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 29300-444). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Unichem Pharmaceuticals (usa), Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (71f96e7f 8660 4b0b Af80 Adc7d4337656 147 1)
A line chart comparing the percentage of subjects improved over baseline to Week 12 using the Brief Pain Inventory-Short Form (BPI-SF) between Pregabalin and placebo groups. The x-axis shows percent improved, and the y-axis shows percent of subjects improved, with Pregabalin showing a consistently higher improvement rate than placebo across the range.*
Fig-01 (77b64701 2992 48b4 B71b Eeb7d33ab813 01)
Chemical structure of Pregabalin showing its molecular arrangement including an amine group, a carboxylic acid group, and a branched hydrocarbon chain. This diagram represents the active ingredient Pregabalin.*
Fig-02 (77b64701 2992 48b4 B71b Eeb7d33ab813 02)
Chemical structure of pregabalin, showing its molecular framework including an amine group (NH2), a carboxylic acid group (COOH), and a chiral center. The illustration depicts connectivity but does not include atom labels beyond those shown for nitrogen and oxygen.*
Fig-11 (77b64701 2992 48b4 B71b Eeb7d33ab813 03)
This chart shows the percentage of patients improved (y-axis) plotted against percent improvement in pain from baseline (x-axis). Two lines compare the effects of Pregabalin 100 mg three times a day and placebo on pain improvement.*
Image (77b64701 2992 48b4 B71b Eeb7d33ab813 04)
A line chart comparing the percentage of patients improved against the percent improvement in pain from baseline. Two lines represent Pregabalin 100 mg three times a day and placebo, showing patient outcomes across varying levels of pain improvement.*
Fig-12 (77b64701 2992 48b4 B71b Eeb7d33ab813 05)
A line graph depicting the percent improvement in pain from baseline plotted against the percent of patients improved for different dosages of Pregabalin (75 mg, 150 mg, and 300 mg taken twice a day) compared to placebo. The graph shows separate curves for each dosage and placebo illustrating their relative effectiveness over a range of percent improvements.*
Image (77b64701 2992 48b4 B71b Eeb7d33ab813 06)
A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 200 mg three times a day, and a placebo. The graph shows a range from 0 to 100% improvement with vertical marker lines at 30%, 50%, and 70% improvement.*
Image (77b64701 2992 48b4 B71b Eeb7d33ab813 07)
A line graph depicting percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing patient improvement distributions for each treatment.*
Image (77b64701 2992 48b4 B71b Eeb7d33ab813 08)
A bar chart comparing responder rates (%) across different dosages in two studies (Study E1 and Study E3). The x-axis shows dosage groups including placebo and various pregabalin doses, while the y-axis represents responder rate percentages. The chart illustrates increases in responder rates with higher doses of pregabalin compared to placebo.*
Image (77b64701 2992 48b4 B71b Eeb7d33ab813 09)
A dose-response chart showing seizure reduction percentage change from baseline across different pregabalin doses (mg/day). It includes data points from multiple studies (E1 BD, E2 TID, E3 BD, E3 TID) with significant p-values indicated for each dose group compared to placebo.*
Image (77b64701 2992 48b4 B71b Eeb7d33ab813 10)
A bar graph depicting responder rates (%) for three groups: Placebo, 2.5 mg/kg/day, and 10 mg/kg/day dosing. The responder rate increases across the groups, with Placebo at 22.6%, 2.5 mg/kg/day at 29.1%, and 10 mg/kg/day at 40.6%. The sample sizes are 93, 103, and 96 respectively.*
Fig14 (77b64701 2992 48b4 B71b Eeb7d33ab813 11)
A line graph depicting three downward trends over time, each represented by a different line style (solid, dashed, and dotted). Vertical lines mark two specific points on the x-axis. The graph likely shows changes in variables or measurements related to Pregabalin but does not specify exact parameters.*
Figure 10: Time To Loss Of Therapeutic Response, Fibromyalgia Study F2 (kaplan-meier Analysis) (77b64701 2992 48b4 B71b Eeb7d33ab813 12)
A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR over a 180-day period for Pregabalin versus placebo. The solid line represents Pregabalin and the dashed line represents placebo, with the vertical axis showing the percentage without LTR and the horizontal axis showing days.*
Fig-50 (77b64701 2992 48b4 B71b Eeb7d33ab813 13)
A line graph comparing the percent of subjects improved over placebo from baseline to Week 16 BOCF for Pregabalin and placebo groups. The x-axis represents percent improvement from 0 to 100%, and the y-axis shows the percent of subjects improved, ranging from 0 to 100%. Two lines display the different improvement rates for Pregabalin and placebo.*
Image (77b64701 2992 48b4 B71b Eeb7d33ab813 14)
Fig-04 (77b64701 2992 48b4 B71b Eeb7d33ab813 15)
Label for Pregabalin Capsules 25 mg by Unichem Pharmaceuticals (USA), Inc. The label includes dosing instructions, storage conditions (20°C to 25°C), and states the capsules are packaged in child-resistant containers. It specifies dispensing information for pharmacists and lists manufacturing details of Unichem Laboratories Ltd. and Unichem Pharmaceuticals (USA), Inc. The label also shows a barcode, NDC number 29300-439-19, and the container size of 90 capsules.*
Fig-05 (77b64701 2992 48b4 B71b Eeb7d33ab813 16)
Pregabalin 50 mg capsules oral label from Unichem Pharmaceuticals (USA), Inc. The label includes storage instructions, dispensing requirements, a barcode, and manufacturer information for Unichem Laboratories Ltd., India. It specifies 90 capsules per container and a caution to keep out of reach of children.*
Fig-75 (77b64701 2992 48b4 B71b Eeb7d33ab813 17)
Label for Pregabalin 75 mg capsules by Unichem Pharmaceuticals (USA), Inc. Features dosage form as capsules, strength 75 mg, and prescription status Rx only. Includes storage instructions, barcode, and manufacturer details from Unichem Laboratories Ltd., India, with manufacturing location in New Jersey, USA. Package contains 90 capsules.*
Fig-06 (77b64701 2992 48b4 B71b Eeb7d33ab813 18)
Pregabalin Capsules 100 mg oral dosage form label from Unichem Pharmaceuticals (USA), Inc. The label indicates a package of 90 capsules with storage instructions and a note for pharmacists to dispense the Medication Guide. The label displays manufacturer details for Unichem Laboratories Ltd., India, and Unichem Pharmaceuticals (USA), Inc.*
Fig-07 (77b64701 2992 48b4 B71b Eeb7d33ab813 19)
Label for Pregabalin Capsules 150 mg by Unichem Pharmaceuticals (USA), Inc. The capsule strength is 150 mg. The label states storage instructions, dispensing information, and includes a barcode. The package contains 90 capsules and is marked Rx Only. Manufacturer details include Unichem Laboratories Ltd., India, and Unichem Pharmaceuticals (USA), Inc., New Jersey.*
Fig-08 (77b64701 2992 48b4 B71b Eeb7d33ab813 20)
Label for Pregabalin Capsules 200 mg by Unichem Pharmaceuticals (USA), Inc. The capsule strength is 200 mg. The label includes storage instructions, dispensing information, and a barcode. The capsules are packaged 90 per container and marked Rx only. Manufactured by Unichem Laboratories Ltd., India, and for Unichem Pharmaceuticals (USA), Inc.*
Fig-09 (77b64701 2992 48b4 B71b Eeb7d33ab813 21)
Label for Pregabalin Capsules 225 mg, an oral prescription medication manufactured by Unichem Laboratories Ltd. and labeled by Unichem Pharmaceuticals (USA), Inc. The carton contains 90 capsules. The label includes storage instructions, dosage guidance, and a barcode.*
Fig-10 (77b64701 2992 48b4 B71b Eeb7d33ab813 22)
Label for Pregabalin Capsules 300 mg by Unichem Pharmaceuticals (USA), Inc. The label indicates an oral capsule dosage form with a package containing 90 capsules. Storage instructions specify 20°C to 25°C with permitted excursions. The product is for prescription use only and includes manufacturer details for Unichem Laboratories Ltd. and Unichem Pharmaceuticals (USA), Inc.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
